Chromadex CORP 10-Q quarterly reports

Niagen Bioscience reported a 3% increase in net sales for Q1 2026, driven by growth in its consumer products and ingredients segments, alongside a rise in net income.

Niagen Bioscience, Inc. reported significant financial improvements for the third quarter and first nine months of 2025, driven by strong sales growth across its consumer products and ingredients segments.

Niagen Bioscience, Inc. announced a significant turnaround in its second quarter, reporting substantial net income and robust revenue growth driven by its consumer products and ingredients segments.

Niagen Bioscience announces a profitable first quarter in 2025, driven by significant growth in both consumer product and ingredient sales.

ChromaDex Corporation announced its Q3 2024 financial results, highlighted by a settlement agreement with Dartmouth College waiving $3.5 million in fees, and a 31% increase in net sales compared to Q3 2023.

ChromaDex Corporation reported a marginal net loss of $15,000 for the second quarter of 2024, despite a 12% increase in net sales compared to the same period last year.

ChromaDex Corporation experienced a minor decrease in net sales for the first quarter of 2024, while strategically increasing research and development investments.